Objective: Bacillus Calmette-Guerin (BCG) immunotherapy is the gold standard treatment for superficial intermediate/high risk of recurrence or progression bladder tumors. However, approximately 30% of patients fail to respond to treatment. Effective BCG therapy needs precise activation of the Th1 immune pathway. Tumor-associated macrophages (TAMs) often assume an immunoregulatory M2 phenotype and may directly interfere with the BCG induced antitumor immune response. Thus, we aim to clarify the influence of TAMs, in particular of the M2-phenotype in stroma and tumor areas, in BCG treatment outcome.
INTRODUCTION
Bladder cancer (BC) is the second most common urologic cancer and has the highest recurrence ratio of any malignancy [1] . Approximately 75-85% of all BC are non-muscle invasive (NMIBC), which includes carcinoma in situ (CIS) and papillary tumors confined to the mucosa or submucosa (Ta/T1) [1] . The NMIBC risk classification divides patients into low, intermediate and high-risk categories for recurrence and progression [1] . The gold standard treatment for intermediate/high risk patients is intravesical instillations with Bacillus CalmetteGuérin (BCG) [1] . However, 30-50% of patients fail to respond, and 15% show progression to muscle-invasive disease. In these cases, radical cystectomy is the treatment to follow [2] .
Intravesical instillations of BCG induce a massive local immune response that is characterized by the expression of cytokines in the bladder, as well as an influx of granulocytes and mononuclear cells (lymphocytes and macrophages) into the tumor areas [3, 4] .
Tumor biology, tumor progression and response to therapy are influence by the tumor microenvironment [5, 6] . These includes stromal cells, infiltrating leukocytes and blood vessels (depending on tumor size), all of which contribute to the so-called tumor stroma [6] . Tumorassociated macrophages (TAMs) are a major component of the tumor stroma that contribute to tumor progression in several types of cancer [6, 7] .
Macrophages are polarized in two distinct functional forms, M1 and M2 [6] [7] [8] . The classical or M1 macrophages activate type 1 helper cells (Th1) that have the capability to kill pathogens, produce IL-2, IL-12 and pro-inflammatory cytokines that promote responses like cytotoxic T-cell activation [8] . In contrast, alternatively-activated M2 macrophages express low levels of IL-12 and high levels of IL-4 and IL-10, promoting Th2 cytokines that inhibit Th1 responses [7] . However, associated to the tumor, M2-polarized macrophages comprise multiple subtypes that may contribute to immunosupression, angiogenesis, cell invasion and metastasis, depending on the microenvironment [5, 9] . Also, cytokines and chemokines released by the tumor may recruit and modulate monocyte differentiation into M2-macrophages lineages that may differ from those in the stroma [6, 7] . As such, a detailed evaluation of macrophage phenotypes in both the tumor and the stroma as well as their microenvironment is needed to fully understand how M2-macrophages influence tumor behavior and ultimately the response to treatment.
The studies presented so far indicate that higher TAM counts are associated with lower recurrence free survival and high risk of BCG treatment failure [10] [11] [12] . Nevertheless, these conclusions were based exclusively on CD68 expression, a macrophage lineage marker that does not allow the discrimination between M1 and M2 phenotypes therefore adding bias to these observations [13, 14] . Also, patients that respond to BCG commonly release large amounts of Th1 cytokines [15] , whereas high levels of Th2 cytokines (i.e. IL-4 and IL-10) seem to be related with BCG failure [16] . These observations support the idea that effective BCG therapy requires precise activation of the Th1 immune pathway [17, 18] . However, TAMs assuming an immunoregulatory M2-phenotype release Th2 cytokines that may directly interfere with the BCG induced antitumor immune response [7, 16, 18] . Still, no direct evidences have been presented supporting the association between higher counts of M2-polarized macrophages and the failure of BCG treatment.
Furthermore, macrophages in different localizations may present different phenotypes induced by the microenvironment. For example, oxygen shortage is known to promote an accumulation of angiogenic M2-macrophages in tumor hypoxic areas, where HIF-1α enhances the expression of VEGF and decreases the production of classical Th2 cytokines [19] . Despite these observations, the influence of hypoxia in the modulation of M2-polarized macrophage distribution in bladder tumors and stroma and its association with BCG treatment outcome also remains unevaluated.
In resume, a clarification about the expression pattern of M2-macrophages in intermediate and high-risk of recurrence bladder tumors and the influence of hypoxia is needed to disclose their true predictive value in the context of BCG response. In this study we devoted to this matter by evaluating the overall TAMs (CD68 + ) as well as the M2 phenotype, based on CD163 expression, in both stroma and tumor areas. As outlined, we correlated our findings with HIF-1α expression to disclose the influence of hypoxia in M2-macrophage accumulation and treatment outcome.
METHODS

Cohort of Patients
In this study were included 99 formalin fixed paraffin embedded (FFPE) tissues from patients treated with transurethral resection of bladder tumor (TURBT) and then submitted to BCG immunotherapy in the Urology Department of Portuguese Institute of Oncology -Oporto (IPO-Porto), between 1998 and 2006. All patients received induction BCG therapy for 6 consecutive weeks, starting 2-3 weeks after surgery (iBCG) and were then submitted to mBCG schedule (the one used in our institute is iBCG + maintenance protocol with 2-weekly instillations every 3 months during 2 years). The iBCG group includes patients treated before the European Association of Urology guidelines recommending the mBCG scheme [20] and patients showing significant intolerance to long BCG treatment.
The average age of the patients was 68 years (range 41-85). The male:female ratio was 84:15. The patients were followed every 3 months during the first year, every 6 months in the second year and every 12 months thereafter by cystoscopy and urine cytology. The median follow-up time was 68 months (range:10-163months).
Recurrence was defined as the appearance of a tumor after the beginning of the treatment, with at least one tumor-free cystoscopy and cytology in-between. BCG failure, as opposed BCG success, was defined as patients submitted to BCG treatment with tumor recurrence. Finally, recurrence-free survival (RFS) was defined as the period between the beginning of the treatment and either recurrence or the most recent tumour-free cystoscopy and High (10-50% or >50% nuclear or cytoplasmic staining).
Statistical Analysis
Statistical data analysis was performed using the IBM Statistical Package for Social 
RESULTS
Association of Clinical and clinical characteristics with BCG treatment outcome
Approximately 42.4% of the patients presented recurrences, with the median recurrence time of 38.5 months (range: 10-122). The median follow-up time of the patients free of recurrence was 97 months (range: 13-163). accordingly. Namely, a higher frequency of patients with BCG failure presented HS (above the 25th percentile) for CD163+ macrophages (83%) when compared with ones where BCG was successful (74%); yet this association was not statistically significant.
We also observed that the LS phenotype was always associated with low macrophage tumor counts (LT) (Fig. 1A) . Furthermore, the CD163 + LS phenotype (associated with LT)
presented BCG treatment response rates similar to the cases with HS and high tumor CD163 + counts (HT; >75th percentile - Fig. 1B ). Based on these observations, we decided to merge these two groups (LS/LT and HS/HT) and compare it with the cases presenting HS but LT CD163 + counts. Taking into consideration the low CD163 + counts presented by the tumors included in the LT phenotype (<10 macrophages) in comparison with the high stroma counts, the group was termed high stroma-predominant CD163 + macrophage group (HSP, Fig. 1C ).
This comparison highlighted that a higher percentage of patients presenting BCG failure had HSP when compared to the ones where the treatment was successful (69% vs. 46%; p=0.020; Sensivity: 54.4%; Specifity: 69.1%; Fig. 2 Table 3 ).
CD163 + Macrophages and expression of HIF-1α
The association between CD163 + macrophages counts within tumor and hypoxia was evaluated based on HIF-1α expression. The expression of HIF-1α is represented by a nuclear and cytoplasmic staining at the invasive front of the tumor. It was also observed that tumor areas with high density of CD163 + macrophages expressed high amounts of HIF-1α (Fig. 4A&B ).
On the other hand, tumor areas with low CD163 + macrophages counts, independently of the counts in the stroma, presented lower expression of HIF-1α (Fig. 4C&D) . In resume, while the HSP and LS (that also present LT counts) phenotypes were associated with tumors showing low degree of hypoxia, samples presenting the HS/HT phenotypes are associated with highly hypoxic tumors (p<0.001). However, the expression of HIF-1α was not associated with BCG treatment outcome.
Discussion
Although BCG immunotherapy is the primary treatment option for intermediate/high risk bladder tumors, the failure rate is over 30% [1] . Therefore the identification of biomarkers able to predict treatment failure and to provide an early identification of those patients better served by alternative therapies is crucial for the management of this disease [4] . There are some biomarkers emerging in the literature, but at the moment none could be set as reliable to translate into clinical practice [21, 22] .
One of the biomarkers with consistent results was the presence of TAMs in bladder tumors prior to BCG treatment, although more studies are needed to validate its relevance [10-12, 21, 22] . On the other hand, the marker used was CD68, a lineage marker found in both M1 and M2 macrophages [7] . Several authors showed that in order to accurately determine TAMs influence in prognosis and treatment outcome, M2-specific markers, such as CD163, should be used [23] [24] [25] [26] . To address this subject we investigated the influence of TAMs (CD68  + ) and also the M2-polarized macrophage phenotype (CD163 + ), in the context of BCG treatment outcome. Taking into consideration that the microenvironment plays a determinant role in the modulation of the macrophage lineages we evaluated independently the tumor and the stroma.
We started by seeking associations between the patient's clinicopathological characteristics and the BCG treatment outcome and found that it was influenced by age and treatment scheme (iBCG, mBCG). Therefore, these variables were considered potential confounders and were taken into account in multivariate analysis models to assess the TAMs influence in BCG outcome. We also observed that CD68 + and CD163 + macrophages counts in both the stroma and tumor were correlated with higher stage, grade and tumor size. Similar results were observed by other authors for bladder cancer using CD68 [12, 27] . The CD163 + macrophages identification has also been associated with poor prognosis in several types of cancer [23, 28] ; however this is the first study suggesting that the M2-subtype may be a characteristic of high-risk of recurrence/progression bladder tumors.
Three studies have been presented supporting the idea that a higher density of macrophages in the tumor and its surroundings may be associated with BCG treatment failure [10] [11] [12] . However, we observed no associations between CD68 + macrophage counts in stroma and in tumor nests and the outcome. Even though contradictory these results may stem from the fact that two of this studies were conducted in a low number of samples (27 and 46) and did not take into consideration the localization of the macrophages. A third study involving a localization-based analysis in CIS, described that cases with a low density of tumor CD68 + macrophages presented higher recurrence-free rate. However the reduced number of CIS in our series does not allow an accurate comparison. Nevertheless, whether macrophage density influences treatment outcome in different ways depending on the histology of the tumor warrants a deeper evaluation.
Contrastingly, we observed that a high density of M2-polarized macrophage counts in the stroma but not in the tumor related with BCG treatment failure. Interestingly, cases presenting a high density of macrophages in the tumor presented a more favourable outcome.
Furthermore, these cases behaved similarly to those presenting an overall low density of M2 macrophages (LT/LS). These results suggest that M2-macrophages may be influencing treatment outcome in different ways possibly due to the influence of differentiated micro environmental stimuli in the stroma and the tumor.
Since TAMs may be found in vascularised stroma but also significantly accumulate in hypoxic areas within the tumor [19, 29, 30] , we hypothesized that differences in CD163 expression between tumor areas could be the result of hypoxia. This was confirmed by the association between high tumor CD163 + macrophage counts and high expression of the hypoxia marker HIF-1α within tu or areas; con ersely, in speci ens with High stromapredominant CD163 + counts (and respectively low tumor counts), HIF-1expression within tumor areas was low. These observations suggest that hypoxic conditions may dictate the accumulation of CD163 + macrophages in bladder tumor areas.
Hypoxia not only seems to dictate the accumulation of macrophages in the tumor but may also modulate the M2-macrophage phenotype. In particular, hypoxia is known to enhance the expression of angiogenic factors, producing high amounts of VEGF and other proinflammatory cytokines like TNF-α, IL-1β, MIF and COX2 that act as pro oters of a Th1 mediated response known to favour BCG action [19] . On the other hand, normoxia may favour the M2 immunosuppressive phenotype and the downregulation of molecules implicated in immunological activation such as IL-12, IL-18, IL-1β and TNFα [5] . This selective pressure also upregulates the expression of Th2-type cytokines, as well as IL-10, IL-1RA and TGF-β, so e of which have been associated with a lack of response to BCG treatment [16] . Based on these observations we hypothesize that hypoxic conditions may favour the accumulation of M2-polarized macrophages in the tumor and also promote their angiogenic phenotype, ultimately leading to a better treatment outcome. Conversely, non-hypoxic or low-hypoxic conditions (low HIF-1α decrease the density of macrophages in the tumor area, maintaining them in the stroma area. We may hypothesize that these macrophages present the immunosupressive phenotype, which in part may explain the higher treatment failure.
Although our results point out that high stroma-predominant CD163 + macrophage counts is a good predictor of recurrence after BCG treatment, some limitations need to be overcome in order to use this biomarker in clinical practice. Namely, efforts should be taken to make the macrophage counts reproductive. 
